Prnewswire·2025-10-09 21:22Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Class Action Details - A class action lawsuit has been filed against Cytokinetics, alleging that the company made false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten [4] - The lawsuit claims that Cytokinetics misrepresented the expected FDA approval timeline, indicating approval in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]